Redditch Medical Acquired by Schülke & Mayr, Delivering Significant Return for Traditum
Redditch Medical, a UK-based cleanroom contamination control specialist, has been acquired by German healthcare company Schülke & Mayr. The deal delivers a significant return for Traditum Private Equity, which invested in the company in 2024. Redditch Medical manufactures the InSpec range of disinfectants and provides technical support, with exports forming most of its turnover.
Redditch Medical, a specialist in cleanroom contamination control solutions based in Sedgefield, has been acquired by Schülke & Mayr, a global leader in infection prevention and control for the pharmaceutical and biotech sectors. The acquisition marks a successful exit for Traditum Private Equity, which invested in the company in early 2024 and supported a management buy-out led by Steve Brown. Under Traditum’s backing, Redditch Medical strengthened its management, expanded operations, launched new products, and achieved significant sales growth. The company manufactures the InSpec range of cleanroom disinfectants and detergents for the life sciences industry and provides technical support, including microbiological and chemical analytics. Exports account for the majority of its turnover, and it employs 44 staff. Following the acquisition, Traditum will retain a stake in Entaco’s remaining divisions, which manufacture surgical needles and medical devices. Steve Brown will remain with Redditch Medical under its new ownership. Schülke & Mayr’s acquisition expands its ability to deliver cleanroom solutions to customers worldwide and supports Redditch Medical’s continued growth across European and global markets. Executives from both companies highlighted the strategic fit and the shared vision of quality, safety, and innovation.
